- Home
- APLT vs ATRA Comparison
APLT vs ATRA Comparison
Compare APLT & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- ATRA
- Stock Information
- Founded
- APLT 2016
- ATRA 2012
- Country
- APLT United States
- ATRA United States
- Employees
- APLT N/A
- ATRA N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APLT Health Care
- ATRA Health Care
- Exchange
- APLT Nasdaq
- ATRA Nasdaq
- Market Cap
- APLT 37.5M
- ATRA 42.9M
- IPO Year
- APLT 2019
- ATRA 2014
- Fundamental
- Price
- APLT $0.40
- ATRA $7.27
- Analyst Decision
- APLT Buy
- ATRA Buy
- Analyst Count
- APLT 7
- ATRA 5
- Target Price
- APLT $6.10
- ATRA $17.75
- AVG Volume (30 Days)
- APLT 1.9M
- ATRA 45.5K
- Earning Date
- APLT 05-20-2025
- ATRA 05-20-2025
- Dividend Yield
- APLT N/A
- ATRA N/A
- EPS Growth
- APLT N/A
- ATRA N/A
- EPS
- APLT N/A
- ATRA N/A
- Revenue
- APLT $455,000.00
- ATRA $128,940,000.00
- Revenue This Year
- APLT $1,768.13
- ATRA N/A
- Revenue Next Year
- APLT $361.28
- ATRA N/A
- P/E Ratio
- APLT N/A
- ATRA N/A
- Revenue Growth
- APLT N/A
- ATRA 1404.02
- 52 Week Low
- APLT $0.30
- ATRA $5.01
- 52 Week High
- APLT $10.62
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- APLT 46.92
- ATRA 53.01
- Support Level
- APLT $0.39
- ATRA $6.90
- Resistance Level
- APLT $0.44
- ATRA $8.65
- Average True Range (ATR)
- APLT 0.04
- ATRA 0.63
- MACD
- APLT 0.01
- ATRA 0.03
- Stochastic Oscillator
- APLT 45.49
- ATRA 44.58
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).